Back

Real-world results of selexipag in treating pulmonary hypertension in a portuguese population

12 May 2024 (13:00 - 15:00)
Organised by: Logo
Congress Presentation Part of: ePosters in valvular and pulmonary 4 Pulmonary Hypertension HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Joana Mesquita Guimaraes

University Hospitals of Coimbra, Coimbra (Portugal)

3 More presentations in this session

Presentation thumbnail
Exploring the clinical relevance of TSAT <21% as an iron deficiency indicator in pulmonary arterial hypertension: a comparative analysis with alternative criteria and existing guidelines
Doctor N. Ilchyshyn (Almada, PT)
Abstract Slides Video
Presentation thumbnail
Long-term survival outcomes and baseline hemodynamics in patients with PAH versus CTEPH
Doctor J. Mesquita Guimaraes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
HFWM: exploring biomarkers in chronic thromboembolic pulmonary hypertension (CTEPH): prognostic significance, and post-PEA dynamics analysis
Doctor A. Cuomo (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in valvular and pulmonary 4

The Event

Event poster

Heart Failure 2024

12 May 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
thumbnail
Congress Presentation
Investigational randomized controlled trial of patients with inoperable chronic thromboembolic pulmonary hypertension treated with riociguat vs selexipag
thumbnail
Congress Presentation
Representativeness of randomized clinical trial criteria among the real-world patients with pulmonary arterial hypertension: an analysis from the FOCUS-PAH registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources